KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference
KALA BIO (NASDAQ:KALA) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York. Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer, will deliver a presentation on December 4, 2024, at 11:30 a.m. ET. The company, which focuses on developing innovative therapies for rare and severe eye diseases, will also be available for one-on-one meetings during the conference. A webcast of the presentation will be accessible through the 'Presentations' section on KALA's website.
KALA BIO (NASDAQ:KALA) ha annunciato la sua partecipazione alla 36ª Conferenza Sanitaria Annuale di Piper Sandler a New York. Kim Brazzell, Ph.D., Responsabile R&D e Direttore Medico, presenterà il suo intervento il 4 dicembre 2024, alle 11:30 ET. L'azienda, che si concentra sullo sviluppo di terapie innovative per malattie oculari rare e gravi, sarà disponibile anche per incontri one-to-one durante la conferenza. Una trasmissione in diretta della presentazione sarà accessibile tramite la sezione 'Presentazioni' sul sito web di KALA.
KALA BIO (NASDAQ:KALA) ha anunciado su participación en la 36ª Conferencia Anual de Atención Médica de Piper Sandler en Nueva York. Kim Brazzell, Ph.D., Jefe de I+D y Director Médico, realizará una presentación el 4 de diciembre de 2024, a las 11:30 a.m. ET. La empresa, que se centra en el desarrollo de terapias innovadoras para enfermedades oculares raras y severas, también estará disponible para reuniones uno a uno durante la conferencia. Una transmisión en vivo de la presentación estará disponible a través de la sección 'Presentaciones' en el sitio web de KALA.
KALA BIO (NASDAQ:KALA)는 뉴욕에서 열리는 Piper Sandler 제36회 연례 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 김 브라젤, 박사, 연구개발 책임자이자 최고 의료 책임자는 2024년 12월 4일 오전 11시 30분 ET에 발표를 할 예정입니다. 희귀하고 심각한 안과 질환을 위한 혁신적인 치료법 개발에 집중하는 이 회사는 컨퍼런스 동안 1대1 회의도 진행할 예정입니다. 발표의 웹캐스트는 KALA 웹사이트의 '발표' 섹션을 통해 접근 가능할 것입니다.
KALA BIO (NASDAQ:KALA) a annoncé sa participation à la 36ème Conférence Annuelle de Santé de Piper Sandler à New York. Kim Brazzell, Ph.D., Responsable R&D et Directeur Médical, fera une présentation le 4 décembre 2024 à 11h30 ET. L'entreprise, qui se concentre sur le développement de thérapies innovantes pour les maladies oculaires rares et sévères, sera également disponible pour des réunions individuelles pendant la conférence. Un webinaire de la présentation sera accessible dans la section 'Présentations' sur le site de KALA.
KALA BIO (NASDAQ:KALA) hat seine Teilnahme an der 36. jährlichen Healthcare-Konferenz von Piper Sandler in New York angekündigt. Kim Brazzell, Ph.D., Leiter der F&E und Chief Medical Officer, wird am 4. Dezember 2024 um 11:30 Uhr ET eine Präsentation halten. Das Unternehmen, das sich auf die Entwicklung innovativer Therapien für seltene und schwere Augenkrankheiten konzentriert, wird während der Konferenz auch für persönliche Gespräche zur Verfügung stehen. Ein Webcast der Präsentation wird über den Bereich 'Präsentationen' auf der Website von KALA zugänglich sein.
- None.
- None.
ARLINGTON, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY on Wednesday, December 4, 2024 at 11:30 a.m. ET. Management will also be available for one-on-one meetings on Wednesday, December 4, 2024.
To access the webcast and subsequent archived recording of the presentation, please visit the “Presentations” section of the KALA website at www.kalarx.com.
About KALA BIO, Inc.
KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.
Investor Contact:
Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200
FAQ
When is KALA BIO presenting at the Piper Sandler Healthcare Conference 2024?
Who will represent KALA BIO at the Piper Sandler Healthcare Conference 2024?
How can investors access KALA BIO's Piper Sandler Conference presentation?
What is KALA BIO's main business focus according to the announcement?
